Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 3:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: EGFR Mutation Clear all

Completed Phase 3 Interventional Results available

A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

NCT02864251

View directory record Official record

Conditions: Non-Small-Cell Lung Carcinoma
Interventions: Nivolumab, Ipilimumab, Pemetrexed, Cisplatin, Carboplatin; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older

Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 18
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 12 more

Source: ClinicalTrials.gov public record

Updated Sep 27, 2023 · Synced May 22, 2026, 3:37 AM EDT

Completed Phase 1Phase 2 Interventional Results available

G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

NCT03455829

View directory record Official record

Conditions: Carcinoma, Non-Small-Cell Lung, Lung Cancer, Non-small Cell Lung Cancer
Interventions: G1T38, Osimertinib; Drug
Lead sponsor: G1 Therapeutics, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 8
States / cities: Beverly Hills, California • Santa Monica, California • Santa Rosa, California + 5 more

Source: ClinicalTrials.gov public record

Updated May 5, 2023 · Synced May 22, 2026, 3:37 AM EDT

Terminated Phase 2 Interventional

Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

NCT03318939

View directory record Official record

Conditions: NSCLC
Interventions: Poziotinib; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older

Enrollment: 648 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 43
States / cities: Phoenix, Arizona • Arcadia, California • Duarte, California + 37 more

Source: ClinicalTrials.gov public record

Updated Apr 2, 2024 · Synced May 22, 2026, 3:37 AM EDT

Withdrawn No phase listed Observational

T790M Mutation Positive 2nd Line STandard of cAre Registry

NCT02368990

View directory record Official record

Conditions: Non Small Cell Lung Cancer
Interventions: Not listed
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older

Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Kentucky, Kentucky • Maryland City, Maryland • Langhorne, Pennsylvania

Source: ClinicalTrials.gov public record

Updated Jul 7, 2015 · Synced May 22, 2026, 3:37 AM EDT

Active, not recruiting Phase 3 Interventional

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

NCT05607550

View directory record Official record

Conditions: Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations
Interventions: furmonertinib 240 mg oral, daily, furmonertinib 160 mg oral, daily, platinum-based chemotherapy; Drug
Lead sponsor: ArriVent BioPharma, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 69
States / cities: Daphne, Alabama • Yuma, Arizona • Fayetteville, Arkansas + 64 more

Source: ClinicalTrials.gov public record

Updated Jun 21, 2025 · Synced May 22, 2026, 3:37 AM EDT

Terminated Phase 3 Interventional Results available

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

NCT05493501

View directory record Official record

Conditions: NSCLC
Interventions: Aumolertinib monotherapy, Osimertinib monotherapy, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel, Nab paclitaxel, Gemcitabine; Drug
Lead sponsor: EQRx International, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 8
States / cities: Springdale, Arkansas • Hollywood, Florida • Pembroke Pines, Florida + 5 more

Source: ClinicalTrials.gov public record

Updated May 1, 2024 · Synced May 22, 2026, 3:37 AM EDT

Completed Phase 1 Interventional Results available

Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)

NCT02157883

View directory record Official record

Conditions: Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
Interventions: Pharmacokinetic sampling, AZD9291, Itraconazole; Procedure · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years

Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 2
States / cities: San Diego, California • Cleveland, Ohio

Source: ClinicalTrials.gov public record

Updated Nov 18, 2025 · Synced May 22, 2026, 3:37 AM EDT

Completed Phase 1Phase 2 Interventional

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

NCT03602079

View directory record Official record

Conditions: HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer, Salivary Gland Cancer, Salivary Gland Tumor, Salivary Gland Carcinoma, Salivary Gland Neoplasms, Lung Cancer, Colo-rectal Cancer, Rare Diseases, Solid Tumor, Recurrent Gastric Cancer, Recurrent Colon Cancer, Recurrent Breast Cancer, Head and Neck Cancer, Head and Neck Carcinoma, Bladder Cancer, Cervical Cancer, Liver Cancer, Bile Duct Cancer, Urologic Cancer, Pancreatic Cancer, Prostate Cancer, Recurrent Prostate Cancer, Rectal Cancer, Recurrent Ovarian Carcinoma, Recurrent Renal Cell Cancer, Rectal Cancer Stage II, Rectal Cancer Stage I, Rectal Cancer Stage III, Skin Cancer, Mouth Cancer, Lip Cancer Stage I, Tongue Cancer, Breast Neoplasm Malignant Primary, Larynx Cancer, Tonsil Cancer, Palate Cancer, Mucoepidermoid Carcinoma, Primary Peritoneal Carcinoma, Mucinous Adenocarcinoma Gastric, Mucinous Breast Cancer Recurrent, Cholangiocarcinoma
Interventions: A166; Drug
Lead sponsor: Klus Pharma Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 10
States / cities: Sarasota, Florida • Boston, Massachusetts • Detroit, Michigan + 7 more

Source: ClinicalTrials.gov public record

Updated Aug 2, 2023 · Synced May 22, 2026, 3:37 AM EDT

Recruiting Phase 2Phase 3 Interventional

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

NCT07005102

View directory record Official record

Conditions: Non-Squamous Non-Small Cell Lung Cancer
Interventions: Standard of Care, Telisotuzumab Adizutecan, Osimertinib (Osi), Cisplatin, Carboplatin, Pemetrexed; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older

Enrollment: 854 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2036
U.S. locations: 13
States / cities: Chandler, Arizona • Los Angeles, California • Newport Beach, California + 10 more

Source: ClinicalTrials.gov public record

Updated May 12, 2026 · Synced May 22, 2026, 3:37 AM EDT

Terminated Phase 4 Interventional Results available

Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)

NCT02695290

View directory record Official record

Conditions: Carcinoma, Non-Small-Cell Lung, ErbB Receptors
Interventions: Afatinib; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older

Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Fountain Valley, California

Source: ClinicalTrials.gov public record

Updated Sep 17, 2017 · Synced May 22, 2026, 3:37 AM EDT

Recruiting Phase 1 Interventional

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

NCT05681780

View directory record Official record

Conditions: Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer
Interventions: Tumor-infiltrating Lymphocytes (TIL), Nivolumab, Cyclophosphamide, Fludarabine, Tumor-infiltrating Lymphocyte Therapy, Interleukin-2 (IL2); Biological · Drug · Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older

Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Source: ClinicalTrials.gov public record

Updated Mar 30, 2026 · Synced May 22, 2026, 3:37 AM EDT

Completed Phase 1Phase 2 Interventional Results available

A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer

NCT02321540

View directory record Official record

Conditions: Lung Cancer
Interventions: Ibrutinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older

Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Source: ClinicalTrials.gov public record

Updated Oct 24, 2023 · Synced May 22, 2026, 3:37 AM EDT

Completed Phase 1 Interventional

Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors

NCT02926768

View directory record Official record

Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Adenocarcinoma
Interventions: CK-101; Drug
Lead sponsor: Checkpoint Therapeutics, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 4
States / cities: Sarasota, Florida • St Louis, Missouri • Hackensack, New Jersey + 1 more

Source: ClinicalTrials.gov public record

Updated Jul 25, 2022 · Synced May 22, 2026, 3:37 AM EDT

Completed Phase 2 Interventional Results available

LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations

NCT00525148

View directory record Official record

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: BIBW 2992; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 99 Years

Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 23
States / cities: Bakersfield, California • Beverly Hills, California • Mission Hills, California + 19 more

Source: ClinicalTrials.gov public record

Updated Sep 15, 2016 · Synced May 22, 2026, 3:37 AM EDT

Completed Phase 1 Interventional Results available

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

NCT01999985

View directory record Official record

Conditions: Lung Cancer, Non-small Cell Lung Cancer (NSCLC)
Interventions: Dasatinib - 1A, Afatinib - 1A, Dasatinib - 1B, Afatinib - 1B; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older

Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Tampa, Florida

Source: ClinicalTrials.gov public record

Updated Nov 26, 2020 · Synced May 22, 2026, 3:37 AM EDT

Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)

NCT04765059

View directory record Official record

Conditions: Non-small Cell Lung Cancer
Interventions: Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin, Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years

Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Silver Spring, Maryland • Boston, Massachusetts

Source: ClinicalTrials.gov public record

Updated Apr 20, 2026 · Synced May 22, 2026, 3:37 AM EDT

Completed Phase 2Phase 3 Interventional Results available

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

NCT02438722

View directory record Official record

Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions: Afatinib Dimaleate, Cetuximab, Laboratory Biomarker Analysis; Drug · Biological · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed

Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 638
States / cities: Fort Smith, Arkansas • Hot Springs, Arkansas • Jonesboro, Arkansas + 406 more

Source: ClinicalTrials.gov public record

Updated May 17, 2026 · Synced May 22, 2026, 3:37 AM EDT

Active, not recruiting Phase 1 Interventional

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

NCT03993873

View directory record Official record

Conditions: Advanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations
Interventions: elzovantinib (TPX-0022); Drug
Lead sponsor: Turning Point Therapeutics, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 12
States / cities: La Jolla, California • Orange, California • Denver, Colorado + 8 more

Source: ClinicalTrials.gov public record

Updated Sep 30, 2025 · Synced May 22, 2026, 3:37 AM EDT

Completed Not applicable Interventional Results available

Understanding Mechanisms of Acquired Resistance to BIBW2992

NCT01074177

View directory record Official record

Conditions: Non-small Cell Lung Cancer, EGFR Mutations
Interventions: BIBW 2992; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older

Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Source: ClinicalTrials.gov public record

Updated Mar 8, 2018 · Synced May 22, 2026, 3:37 AM EDT

Active, not recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

NCT07128199

View directory record Official record

Conditions: NSCLC, Stage IB-IIIA, Lung Cancer, Adjuvant, Post-surgical, EGFR, Exon 20, Early Stage Lung Cancer, Uncommon EGFR Mutations
Interventions: Cisplatin, Carboplatin, Pemetrexed, TAS6417, Zipalertinib Matching-placebo; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 30
States / cities: Anchorage, Alaska • Duarte, California • Irvine, California + 26 more

Source: ClinicalTrials.gov public record

Updated May 4, 2026 · Synced May 22, 2026, 3:37 AM EDT

Completed Phase 2 Interventional Results available

Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR

NCT01854034

View directory record Official record

Conditions: Non Small Cell Lung Cancer
Interventions: AUY922; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older

Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 4
States / cities: Boston, Massachusetts

Source: ClinicalTrials.gov public record

Updated Apr 9, 2018 · Synced May 22, 2026, 3:37 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants

NCT06378658

View directory record Official record

Conditions: Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation, Healthy Volunteers
Interventions: BAY2927088, Esomeprazole, Food; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Source: ClinicalTrials.gov public record

Updated Jul 4, 2024 · Synced May 22, 2026, 3:37 AM EDT

Recruiting Phase 1 Interventional

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

NCT07462377

View directory record Official record

Conditions: Epidermal Growth Factor, Epidermal Growth Factor Receptor, Epidermal Growth Factor Receptor Gene Mutation, Non Small Cell, Non Small Cell Lung, Non Small Cell Lung Cancer, Head and Neck, Head and Neck Cancer, Head and Neck Cancers, Head and Neck Squamous Cell Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC, NSCLC (Non-small Cell Lung Cancer), HNSCC, EGFR
Interventions: EPI-326; Drug
Lead sponsor: EpiBiologics; Industry
Eligibility: 18 Years and older

Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 6
States / cities: Los Angeles, California • East Brunswick, New Jersey • Lake Success, New York + 3 more

Source: ClinicalTrials.gov public record

Updated May 7, 2026 · Synced May 22, 2026, 3:37 AM EDT

Terminated Phase 2 Interventional Results available

A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies

NCT04172597

View directory record Official record

Conditions: Breast Cancer, Colorectal Cancer, Solid Tumor, Glioblastome Multiforme
Interventions: Poziotinib Hydrochloride, Loperamide; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older

Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Long Beach, California

Source: ClinicalTrials.gov public record

Updated Mar 12, 2024 · Synced May 22, 2026, 3:37 AM EDT